Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Maureen J B Aarts"'
Autor:
Anne M May, Michel W J M Wouters, Ellen Kapiteijn, John B A G Haanen, Christian U Blank, Maureen J B Aarts, Rik J Verheijden, Astrid A M van der Veldt, Marye J Boers-Sonderen, Franchette W P J van den Berkmortel, Alfonsus J M van den Eertwegh, Jan Willem B de Groot, Jacobus J M van der Hoeven, Geke A P Hospers, Djura Piersma, Rozemarijn S van Rijn, Albert J ten Tije, Gerard Vreugdenhil, Michiel C T van Zeijl, Karijn P M Suijkerbuijk
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Background Immune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adverse events (irAEs). Since these irAEs mimick immunological disease, a female predominance has been speculated on. Nevertheless, no demographic or tum
Externí odkaz:
https://doaj.org/article/e9745cefbc3341ff89aba01c2bbe198f
Autor:
Dirk Grünhagen, Maureen J B Aarts, Ferry A L M Eskens, Kristien B M I Keymeulen, Lukas B Been, Alexander van Akkooi, Mathilde Jalving, Margot E T Tesselaar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Merkel cell carcinoma (MCC) is associated with high recurrence rates and poor survival when metastatic disease is present. The immune checkpoint inhibitor avelumab has shown high response rates (RRs) and durable responses in patients with
Externí odkaz:
https://doaj.org/article/fa9ada41a89c4dfb8d07a291b6836d46
Autor:
Lindsay V. M. Leek, Jessica C. L. Notohardjo, Karlijn de Joode, Eline L. Velker, John B. A. G. Haanen, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Jan Willem B. de Groot, Ellen Kapiteijn, Franchette W. P. J. van den Berkmortel, Hans M. Westgeest, Tanja D. de Gruijl, Valesca P. Retel, Edwin Cuppen, Astrid A. M. van der Veldt, Mariette Labots, Emile E. Voest, Joris van de Haar, Alfons J. M. van den Eertwegh
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract We evaluated the prognostic value of hypoalbuminemia in context of various biomarkers at baseline, including clinical, genomic, transcriptomic, and blood-based markers, in patients with metastatic melanoma treated with anti-PD-1 monotherapy
Externí odkaz:
https://doaj.org/article/0b86698c5e3b43c28f9ef4dd875f5025
Autor:
Maud Rijnders, J. Alberto Nakauma-González, Debbie G. J. Robbrecht, Alberto Gil-Jimenez, Hayri E. Balcioglu, Astrid A. M. Oostvogels, Maureen J. B. Aarts, Joost L. Boormans, Paul Hamberg, Michiel S. van der Heijden, Bernadett E. Szabados, Geert J. L. H. van Leenders, Niven Mehra, Jens Voortman, Hans M. Westgeest, Ronald de Wit, Astrid A. M. van der Veldt, Reno Debets, Martijn P. Lolkema
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic urothelial cancer (mUC), but therapeutic success at the individual patient level varies significantly. Here we identify predictive markers of response, b
Externí odkaz:
https://doaj.org/article/5c826962a5fb45ffbb47fc08f0218098
Autor:
Daan Jan Willem Rauwerdink, Olivier van Not, Melissa de Meza, Remco van Doorn, Jos van der Hage, A. J. M. van den Eertwegh, John B. Haanen, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christiaan U. Blank, Marye J. Boers-Sonderen, Jan Willem B. de Groot, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, A. M. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Karijn P. M. Suijkerbuijk, Ellen Kapiteijn
Publikováno v:
Cancers, Vol 16, Iss 15, p 2656 (2024)
Introduction: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant and advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups. Methods: This m
Externí odkaz:
https://doaj.org/article/02c43e3aab1348c3b7328efdfe95b1b5
Autor:
Bibian M. E. Tullemans, Sanne L. N. Brouns, Frauke Swieringa, Siamack Sabrkhany, Franchette W. P. J. van den Berkmortel, Natascha A. J. B. Peters, Peter de Bruijn, Stijn L. W. Koolen, Johan W. M. Heemskerk, Maureen J. B. Aarts, Marijke J. E. Kuijpers
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Tyrosine kinase inhibitors (TKIs), such as sunitinib, are used for cancer treatment, but may also affect platelet count and function with possible hemostatic consequences. Here, we investigated whether patient treatment with the T
Externí odkaz:
https://doaj.org/article/bac1127f83e544248d1468261a8425b1
Autor:
Pauline A. J. Mendelaar, Debbie G. J. Robbrecht, Maud Rijnders, Ronald deWit, Vanja deWeerd, Teoman Deger, Hans M. Westgeest, Maureen J. B. Aarts, Jens Voortman, John W. M. Martens, Astrid A. M. van derVeldt, José Alberto Nakauma‐González, Saskia M. Wilting, Martijn Lolkema
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 2086-2097 (2022)
Second‐line treatment with immune checkpoint inhibition in patients with metastatic urothelial cancer (mUC) has a low success rate (~ 20%). Circulating tumour‐derived DNA (ctDNA) levels may guide patient stratification, provided that an affordabl
Externí odkaz:
https://doaj.org/article/697816219cc74830a6f744569b38649b
Autor:
Olivier J. van Not, Thijs T. Wind, Rawa K. Ismail, Arkajyoti Bhattacharya, Mathilde Jalving, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. Haanen, Ellen Kapiteijn, Manja Bloem, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Willeke A. M. Blokx, Karijn P. M. Suijkerbuijk, Rudolf S. N. Fehrmann, Geke A. P. Hospers
Publikováno v:
Cancers, Vol 15, Iss 11, p 2922 (2023)
The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are treated with
Externí odkaz:
https://doaj.org/article/f739e4e995b449a0ac7602d6231073ed
Autor:
Melissa M. De Meza, Willeke A. M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. De Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Olivier J. Van Not, Djura Piersma, Rozemarijn S. Van Rijn, Marion Stevense-den Boer, Astrid A. M. Van der Veldt, Gerard Vreugdenhil, Alfonsus J. M. Van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
Publikováno v:
Cancers, Vol 15, Iss 2, p 409 (2023)
Adjuvant BRAF/MEK- and anti-PD-1 inhibition have significantly improved recurrence-free survival (RFS) compared to placebo in resected stage III BRAF-mutant melanoma. However, data beyond the clinical trial setting are limited. This study describes t
Externí odkaz:
https://doaj.org/article/faabeeb4edd44f849ad8df96fdd717f5
Autor:
Melissa M. de Meza, Willeke A. M. Blokx, Han J. Bonenkamp, Cristian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense‐Den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Alfons J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
Publikováno v:
International Journal of Cancer, 153, 2, pp. 389-398
de Meza, M M, Blokx, W A M, Bonenkamp, H J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ', International Journal of Cancer, vol. 153, no. 2, pp. 389-398 . https://doi.org/10.1002/ijc.34485
International Journal of Cancer, 153(2), 389-398. Wiley-Liss Inc.
International Journal of Cancer, 153, 389-398
International Journal of Cancer. Wiley
International Journal of Cancer, 153, 389-398. Wiley
de Meza, M M, Blokx, W A M, Bonenkamp, H J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ', International Journal of Cancer, vol. 153, no. 2, pp. 389-398 . https://doi.org/10.1002/ijc.34485
International Journal of Cancer, 153(2), 389-398. Wiley-Liss Inc.
International Journal of Cancer, 153, 389-398
International Journal of Cancer. Wiley
International Journal of Cancer, 153, 389-398. Wiley
Contains fulltext : 292870.pdf (Publisher’s version ) (Open Access) Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyon